Coave Therapeutics reveals lead gene therapy program, CoTx-10

Coave Therapeutics has announced its lead gene therapy program, CoTx-10, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).

The company describes CoTx-101 as the combination of a “best-in-class in-office delivery procedure with a first-in-class vector” (coAAV-SCS) to achieve deep retinal penetration, broad tissue coverage, and sustained expression of 2 biologics targeting the angiogenesis pathway. The company notes that the in-office procedure offers the highest clinical benefit with the lowest treatment burden on patients.

The company states it plans to complete TPP validating non-human primate studies of CoTx-101 in 2026, with the aim to be IND-ready in 2027.

Rodolphe Clerval, CEO of Coave Therapeutics, commented on the announcement, saying, “The launch of our lead therapeutic suprachoroidal program validates our delivery-first approach to redefining targeted gene therapy. With our first-in-class ligand-conjugated AAVs, we are creating precision vectors that are highly tissue-specific, precisely delivered, and safer, powering targeted gene therapies. CoTx-101 aims to bring patients the ultimate treatment for retinal vascular diseases, offering the efficacy and safety of biologics with the unique durability of gene therapy.”

The company also recently announced data from 2 studies comparing coAAV-SCS-01 with AAV8 and other first- and second-generation capsids via suprachoroidal delivery in NHPs.

Data from the first study showed coAAV-SCS-01 outperformed all other capsids (AAV2, AAV3B, AAV.7m8, AAV.v128, and AAV8) by up to 26 times in targeting RPE-choroid and retinal cells, while being de-targeted from off-target areas such as the iris-ciliary body.

While data from the second study confirmed coAAV-SCS-01’s superiority over AAV8, demonstrating an improved safety profile with de-targeting from the anterior segment of the eye and immune evasion properties, suggesting the potential for safe second-eye treatment.

References:

1. Coave Therapeutics unveils lead gene therapy program for retinal vascular diseases, powered by first-in-class vector for suprachoroidal delivery. Published November 14, 2025. Accessed November 17, 2025. https://coavetx.com/coave-therapeutics-unveils-lead-gene-therapy-program-for-retinal-vascular-diseases-powered-by-first-in-class-vector-for-suprachoroidal-delivery/

2. Coave Therapeutics demonstrates superiority of its novel suprachoroidal capsid at ESGCT Congress 2025. Published October 7, 2025. Accessed November 17, 2025. https://coavetx.com/coave-therapeutics-demonstratessuperiority-of-its-novel-suprachoroidal-capsidat-esgct-congress-2025/